ANI Pharma

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the top and bottom lines: revenue of $266.0M (+25.9% YoY) exceeded the $260.1M expectation, while adjusted diluted EPS of $2.21 outperformed the $2.04 mean estimate. Growth was primarily fueled by a 43.5% YoY surge in Purified Cortrophin Gel, alongside robust performance in the Generics segment. While full-year revenue and EBITDA guidance was reaffirmed, management narrowed the Cortrophin Gel target, reflecting strong demand momentum despite a temporary international shipment delay in the ILUVIEN product line.